起源于主要输乳管的乳腺癌与新导管生成过程:乳腺导管腺癌(DAB)
该文基于瑞典法伦中心医院自1977年以来的乳腺癌影像与长期随访资料,提出起源于主要输乳管的乳腺癌亚型——乳腺导管腺癌(DAB),其经上皮-间质转化形成新导管(新导管生成)并最终形成巨大肿瘤负荷,预后极差,但常被常规诊断为伴或不伴微浸润的导管原位癌(DCIS)。作者建议将其视为独立浸润性亚型以避免治疗不足。
要点
- 起源于主要输乳管的乳腺癌具有6个乳腺影像学生物标志物,可在影像上识别。
- 该亚型经新导管生成形成多分支浸润结构,伴促结缔组织增生反应及导管周围淋巴细胞浸润。
- 当新导管生成伴终末导管小叶单位来源的小型浸润癌时,预后常被低估而导致治疗不足。
核心结论
- 新导管生成(DAB)在表现和预后上与前列腺导管腺癌(DAP)相似,作者建议采用「乳腺导管腺癌(DAB)」这一术语以促进其被识别为独立的浸润性乳腺癌亚型。
研究设计与样本
- 基于瑞典法伦中心医院乳腺摄影科自1977年以来诊断的全部乳腺癌,按乳腺X线肿瘤特征(影像学生物标志物)分类并定期随访四十年,将影像学生物标志物与大范围薄层和厚层组织病理及长期患者结局进行相关性分析。
关键影像表现/征象
- 起源于主要输乳管的乳腺癌在导管内播散,经上皮-间质转化(EMT)持续产生分支新导管,最终形成巨大肿瘤负荷。
- 新导管内充满多层恶性细胞,无附着小叶,通过形成多个浸润性侧支播散。
- 新生导管样结构周围有促结缔组织增生反应(癌相关成纤维细胞,CAFs)及导管周围淋巴细胞浸润。
- 新导管紧密排列成不规则形态,与正常输乳管的分支结构无相似之处。
- 起源于主要导管的乳腺癌有6个影像学生物标志物,在乳腺影像上易于识别,详见配套文章。
临床应用与阅片要点
- 作者提出「乳腺导管腺癌(DAB)」这一术语,以促进其被识别为独立的浸润性乳腺癌亚型;当新导管生成与小卫星/毛刺状或球形/卵圆形浸润癌共存时,预后和管理按较小的浸润肿瘤估计会带来虚假安全感并常导致治疗不足,认识新导管生成为浸润性恶性病变是防止治疗失败的前提。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To call attention to a highly fatal breast cancer subtype arising from the major lactiferous ducts that is currently underdiagnosed as ductal carcinoma in situ (DCIS) with or without microinvasion.
METHOD: All breast cancers diagnosed at the Department of Mammography, Falun Central Hospital, Sweden, since 1977 have been classified according to their mammographic tumour features (imaging biomarkers) and followed up at regular intervals for the past four decades. The imaging biomarkers characteristic of breast cancers apparently arising from the major lactiferous ducts have been correlated with large format thin and thick section histopathology and long-term patient outcome.
RESULTS: Breast cancers arising within the major lactiferous ducts propagate intraductally and produce continuously branching neoducts through epithelial-mesenchymal transformation (EMT), an invasive process termed neoductgenesis, which eventually forms a massive tumour burden. The high fatality of this breast cancer subtype indicates its truly invasive nature, although it is conventionally termed ductal carcinoma in situ, DCIS, terminology which is at odds with its poor long-term patient outcome. The neoducts are filled with multiple layers of malignant cells, have no attached lobules, and propagate by forming multiple invasive side branches. These newly formed duct-like structures are surrounded by a desmoplastic reaction (cancer associated fibroblasts, CAFs) and periductal lymphocytic infiltration. The neoducts are tightly packed together in irregular formations bearing no resemblance to the paniculate branching structure of normal lactiferous ducts. Cancers originating from the major ducts have six imaging biomarkers which can be easily recognized at breast imaging. These are described in detail in an accompanying article.
CONCLUSIONS: Neoductgenesis in the breast, DAB, is similar in appearance and prognosis to ductal adenocarcinoma of the prostate, DAP. We propose the term ductal adenocarcinoma of the breast, DAB, to facilitate its recognition as a distinct invasive breast cancer subtype. The high fatality rates associated with neoductgenesis reflect the failure of current histopathologic diagnostic criteria to effectively guide therapeutic practice. When the neoducts are associated with small stellate/spiculated or spherical/oval-shaped invasive cancers arising from the terminal ductal lobular units (TDLUs), the prognosis and management are erroneously estimated according to the smaller invasive tumour(s), giving a false sense of security often resulting in undertreatment. Recognition that neoductgenesis is an invasive malignancy is a prerequisite for preventing treatment failure.
引用
- Tabár, Dean, Lee Tucker, et al. Breast cancers originating from the major lactiferous ducts and the process of neoductgenesis: Ductal Adenocarcinoma of the Breast, DAB. Eur J Radiol. 2022. PMID: 35605334. doi:10.1016/j.ejrad.2022.110363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。